Tracer library / [211At]At-meta-astatobenzylguanidine

[211At]At-meta-astatobenzylguanidine

Also written as [At-211]meta-astatobenzylguanidine

Radionuclide: At-211 t½ 431 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 0

Pheochromocytoma and paraganglioma

What it is

Compound class: meta-astatobenzylguanidine (MABG), an alpha-emitting radiolabeled guanidine analogue
Target / mechanism: Norepinephrine transporter (NET) PMID 21803183
Clinical application: Targeted alpha therapy for pheochromocytoma or paraganglioma (PPGL) PMID 38805424
Theranostic pair: —

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

Evaluation of pharmacokinetics, safety, and efficacy of [211At] meta-astatobenzylguanidine ([211At] MABG) in patients with pheochromocytoma or paraganglioma (PPGL): A study protocol.
2024 · PLoS One · Clinical study

Need this precursor?We can point you to suppliers for [211At]At-meta-astatobenzylguanidine, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 38805424: 'We are currently conducting an investigator-initiated first-in-human clinical trial to evaluate the pharmacokinetics, safety, and efficacy of [211At] MABG.'. | Stage 28: added indication(s) onc-ppgl from consolidated missing-rubric review. | Stage 30 (2026-09-18): Stage was 'first-in-human clinical trial'; normalised to 'Clinical research', original wording kept here.